Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer
Open accessThe DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
Pancreatic ductal adenocarcinoma is a lethal cancer with fewer than 7% of patients surviving past 5 years. T-cell immunity has been linked to the exceptional outcome of the few long-term survivors, yet the relevant antigens remain unknown. Here we use genetic, immunohistochemical and transcriptional immunoprofiling, computational biophysics, and functional assays to identify T-cell antigens in long-term survivors of pancreatic cancer. Using whole-exome sequencing and in silico neoantigen prediction, we found that tumours with both the highest neoantigen number and the most abundant CD8+ T-cell infiltrates, but neither alone, stratified patients with the longest survival. Investigating the specific neoantigen qualities promoting T-cell activation in long-term survivors, we discovered that these individuals were enriched in neoantigen qualities defined by a fitness model, and neoantigens in the tumour antigen MUC16 (also known as CA125). A neoantigen quality fitness model conferring greater immunogenicity to neoantigens with differential presentation and homology to infectious disease-derived peptides identified long-term survivors in two independent datasets, whereas a neoantigen quantity model ascribing greater immunogenicity to increasing neoantigen number alone did not. We detected intratumoural and lasting circulating T-cell reactivity to both high-quality and MUC16 neoantigens in long-term survivors of pancreatic cancer, including clones with specificity to both high-quality neoantigens and predicted cross-reactive microbial epitopes, consistent with neoantigen molecular mimicry. Notably, we observed selective loss of high-quality and MUC16 neoantigenic clones on metastatic progression, suggesting neoantigen immunoediting. Our results identify neoantigens with unique qualities as T-cell targets in pancreatic ductal adenocarcinoma. More broadly, we identify neoantigen quality as a biomarker for immunogenic tumours that may guide the application of immunotherapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“In rare patients with localized PDAC who are long-term survivors, bacteria can translocate from the intestine into the tumour and control anti-tumour immune activation11,12.”
From Microbiota-derived 3-IAA influences chemotherapy efficacy in pancreatic cancer (2023) · cites this paper as [12]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“On the other hand, the gut microbiota can indirectly increase the immunogenicity of tumor cells by providing tumor cross-antigens to promote the efficacy of ICI [50, 68, 69].”
From Gut microbiota influence immunotherapy responses: mechanisms and therapeutic strategies (2022) · doi:10.1186/s13045-022-01273-9 · cites this paper as [69]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“PDAC tumors from long term survivors have high quantity and quality of neoantigens, and stronger infiltration and activation of CD8+ T cells”
From Tumor Microbiome Diversity and Composition Influence Pancreatic Cancer Outcomes (2019) · cites this paper as Balachandran et al., 2017
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These data suggest that microbial host factors, independent of the genomic composition of the tumor, may determine tumor behavior and patient outcomes.”
From Tumor Microbiome Diversity and Composition Influence Pancreatic Cancer Outcomes (2019) · cites this paper as Balachandran et al., 2017
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Significantly, the aggressive progression of PDAC, characterized by immune evasion and therapeutic resistance, is heavily influenced by the TME (Balachandran et al., 2017).”
From Microphysiological systems as models for immunologically ‘cold’ tumors (2024) · cites this paper as Balachandran et al., 2017
Experimental — accuracy not yet measured
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
The Ensembl Variant Effect Predictor
McLaren, W., Gil, L., Hunt, S. E., Riat, H. S., Ritchie, G. R. S., Thormann, A., Flicek, P., & Cunningham, F. (2016) · Genome Biology · doi:10.1186/s13059-016-0974-4 · Cited by 8,099
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Self-citationPD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609
Spatiotemporal Dynamics of Intratumoral Immune Cells Reveal the Immune Landscape in Human Cancer
Bindea, G., Mlecnik, B., Tosolini, M., Kirilovsky, A., Waldner, M., Obenauf, A. C., Angell, H., Fredriksen, T., Lafontaine, L., Berger, A., et al. (2013) · Immunity · doi:10.1016/j.immuni.2013.10.003 · Cited by 4,422
Genomic analyses identify molecular subtypes of pancreatic cancer
Bailey, P., Chang, D. K., Nones, K., Johns, A. L., Patch, A.-M., Gingras, M.-C., Miller, D. K., Christ, A. N., Bruxner, T. J. C., Quinn, M. C., et al. (2016) · Nature · doi:10.1038/nature16965 · Cited by 3,621
Self-citationWhole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets
Witkiewicz, A. K., McMillan, E. A., Balaji, U., Baek, G., Lin, W.-C., Mansour, J., Mollaee, M., Wagner, K.-U., Koduru, P., Yopp, A., et al. (2015) · Nature Communications · doi:10.1038/ncomms7744 · Cited by 1,115
Two FOXP3+CD4+ T cell subpopulations distinctly control the prognosis of colorectal cancers
Saito, T., Nishikawa, H., Wada, H., Nagano, Y., Sugiyama, D., Atarashi, K., Maeda, Y., Hamaguchi, M., Ohkura, N., Sato, E., et al. (2016) · Nature Medicine · doi:10.1038/nm.4086 · Cited by 871
Immune cell infiltration as an indicator of the immune microenvironment of pancreatic cancer
Ino, Y., Yamazaki-Itoh, R., Shimada, K., Iwasaki, M., Kosuge, T., Kanai, Y., & Hiraoka, N. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.32 · Cited by 849
Gros, A., Parkhurst, M. R., Tran, E., Pasetto, A., Robbins, P. F., Ilyas, S., Prickett, T. D., Gartner, J. J., Crystal, J. S., Roberts, I. M., et al. (2016) · Nature Medicine · doi:10.1038/nm.4051 · Cited by 829
Cited by
Items 701–800 of 1,001
Dugnani, E., Sordi, V., Pellegrini, S., Chimienti, R., Marzinotto, I., Pasquale, V., Liberati, D., Balzano, G., Doglioni, C., Reni, M., et al. (2018) · Pancreatology · doi:10.1016/j.pan.2018.09.006 · Cited by 14
Proteogenomic discovery of cancer antigens: Neoantigens and beyond
Kanaseki, T., Tokita, S., & Torigoe, T. (2019) · Pathology International · doi:10.1111/pin.12841 · Cited by 13
Presence and structure‐activity relationship of intrinsically disordered regions across mucins
Carmicheal, J., Atri, P., Sharma, S., Sushil Kumar, K., Venkata, R. C., Kulkarni, P., Salgia, R., Ghersi, D., Kaur, S., & Batra, S. K. (2020) · The FASEB Journal · doi:10.1096/fj.201901898rr · Cited by 12
Construction of a novel bispecific fusion protein to enhance targeting for pancreatic cancer imaging
Wang, Q., Yan, H., Wang, Z., Li, Z., Li, D., Li, Z., Wang, K., Tian, J., & Zhao, X. (2020) · Biomaterials · doi:10.1016/j.biomaterials.2020.120161 · Cited by 11
Wang, G., Wan, H., Jian, X., Li, Y., Ouyang, J., Tan, X., Zhao, Y., Lin, Y., & Xie, L. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/697011 · Cited by 12
InvitroSPI and a large database of proteasome-generated spliced and non-spliced peptides
Roetschke, H. P., Rodriguez-Hernandez, G., Cormican, J. A., Yang, X., Lynham, S., Mishto, M., & Liepe, J. (2023) · Scientific Data · doi:10.1038/s41597-022-01890-6 · Cited by 12
Panoramic tumor microenvironment in pancreatic ductal adenocarcinoma
Li, X., Hou, W., Xiao, C., Yang, H., Zhao, C., & Cao, D. (2024) · Cellular Oncology · doi:10.1007/s13402-024-00970-6 · Cited by 13
McMorrow, R., de Bruijn, H. S., Farina, S., van Ardenne, R. J. L., Que, I., Mastroberardino, P. G., Robinson, D. J., Mezzanotte, L., & Löwik, C. W. G. M. (2024) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-23-0733 · Cited by 13
The dual role of gut microbiota in pancreatic cancer: new insights into onset and treatment
Cheng, H., Guo, H., Wen, C., Sun, G., Tang, F., & Li, Y. (2025) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359251324882 · Cited by 18
Evolving concepts in adjuvant/neoadjuvant therapy for resectable pancreas cancer
Bryant, J. M., Ruffolo, L. I., Soares, K. C., Hoffe, S. E., & Lowy, A. M. (2025) · Journal of Clinical Investigation · doi:10.1172/jci191944 · Cited by 12
Autologous multiantigen-targeted T cell therapy for pancreatic cancer: a phase 1/2 trial
Musher, B., Vasileiou, S., Smaglo, B. G., Robertson, C. S., Wu, M., Wang, T., Watanabe, A., Kuvalekar, M., Velazquez, Y., Ketkar, S., et al. (2026) · Nature Medicine · doi:10.1038/s41591-025-04043-5 · Cited by 14
Cherkassky, L., Oshi, M., Abdelfatah, E., Wu, R., Takabe, Y. J., Yan, L., Endo, I., & Takabe, K. (2022) · PubMed Central · Cited by 14
Neoantigens and their clinical applications in human gastrointestinal cancers
Eshkiki, Z. S., Agah, S., Tabaeian, S. P., Sedaghat, M., Dana, F., Talebi, A., & Akbari, A. (2022) · World Journal of Surgical Oncology · doi:10.1186/s12957-022-02776-y · Cited by 11
Huang, Y., Gong, P., Su, L., & Zhang, M. (2023) · Scientific Reports · doi:10.1038/s41598-023-47223-4 · Cited by 10
Up-to-Date Tailored Systemic Treatment in Pancreatic Ductal Adenocarcinoma
Fong, C., Burke, E., Cunningham, D., & Starling, N. (2019) · Gastroenterology Research and Practice · doi:10.1155/2019/7135437 · Cited by 10
Prognostic significance of p16 protein in pancreatic ductal adenocarcinoma
Iwatate, Y., Hoshino, I., Ishige, F., Itami, M., Chiba, S., Arimitsu, H., Yanagibashi, H., Nagase, H., Yokota, H., & Takayama, W. (2020) · Molecular and Clinical Oncology · doi:10.3892/mco.2020.2047 · Cited by 11
Keenan, B. P., Loon, K. V., Khilnani, A. D., Fidelman, N. A., Behr, S. C., Atreya, C. E., & Oh, D. Y. (2021) · Anticancer Research · doi:10.21873/anticanres.15080 · Cited by 11
Bioinformatic Analysis of Prognostic and Immune-Related Genes in Pancreatic Cancer
Li, Z., Hu, C., Yang, Z., Yang, M., Fang, J., & Zhou, X. (2021) · Computational and Mathematical Methods in Medicine · doi:10.1155/2021/5549298 · Cited by 11
Vaccines for Non-Viral Cancer Prevention
Bayó, C., Jung, G., Español‐Rego, M., Balaguer, F., & Benítez‐Ribas, D. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222010900 · Cited by 11
Perrier, A., Hainaut, P. L., Guenoun, A., Nguyen, D.-P., Lamy, P., Guerber, F., Troalen, F., Denis, J. A., & Boissan, M. (2022) · Bulletin du Cancer · doi:10.1016/j.bulcan.2021.12.005 · Cited by 13
Genetic Alterations Predict Long-Term Survival in Ductal Adenocarcinoma of the Pancreatic Head
Safi, S. A., Häberle, L., Goering, W., Keitel, V., Fluegen, G., Stoecklein, N. H., Rehders, A., Knoefel, W. T., & Esposito, I. (2022) · Cancers · doi:10.3390/cancers14030850 · Cited by 10
Breaking the Immune Complexity of the Tumor Microenvironment Using Single-Cell Technologies
Caligola, S., Sanctis, F. D., Canè, S., & Ugel, S. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.867880 · Cited by 11
Huang, Q., Peng, X., Li, Q., Zhu, J., Xue, J., & Jiang, H. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1111494 · Cited by 11
He, Y., Huang, W. J., Tang, Y., Li, Y., Peng, X., Li, J., Wu, J. Y., You, N., Li, L., Liu, C., et al. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1167144 · Cited by 11
Widespread Immunogenic Poly-Epitope Frameshift Mutations in Microsatellite Unstable TumorsPreprint
Roudko, V., Bozkus, C. C., Orfanelli, T., Blank, S. V., Greenbaum, B. D., & Bhardwaj, N. (2019) · SSRN Electronic Journal · doi:10.2139/ssrn.3411246 · Cited by 11
Self-citationHalle-Smith, J. M., Hall, L. A., Powell-Brett, S. F., Merali, N., Frampton, A. E., Beggs, A. D., Moss, P. A. H., & Roberts, K. J. (2023) · Cancers · doi:10.3390/cancers15215140 · Cited by 10
Prediction of tumor-specific splicing from somatic mutations as a source of neoantigen candidates
Lang, F., Sorn, P., Suchan, M., Henrich, A., Albrecht, C. H., Köhl, N., Beicht, A., Riesgo-Ferreiro, P., Holtsträter, C., Schrörs, B., et al. (2024) · Bioinformatics Advances · doi:10.1093/bioadv/vbae080 · Cited by 12
Friends close, enemies closer: the complex role of the microbiome in antitumor immunity
Patra, D., Dev, G., Hand, T. W., & Overacre-Delgoffe, A. E. (2025) · Current Opinion in Immunology · doi:10.1016/j.coi.2025.102537 · Cited by 11
Treatment Innovations in Pancreatic Cancer: Putting Patient Priorities First
Reiss, K. A., Soares, K. C., Torphy, R. J., & Gyawali, B. (2025) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk-25-473204 · Cited by 10
Elucidating DNA Damage-Dependent Immune System Activation
Deligianni, E., Papanikolaou, C., Terpos, E., & Souliotis, V. L. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26125849 · Cited by 12
Zhong, Y., Zhang, D., Ding, F., Zhang, H., Guo, Y., Huang, Q., Liu, G., Zhang, X., & Weng, S. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2025.115421 · Cited by 9
Personalized Neo-Epitope Vaccines for Cancer Treatment
Vormehr, M., Diken, M., Türeci, Ö., Şahin, U., & Kreiter, S. (2019) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-030-23765-3_5 · Cited by 9
Hashimoto, A., Handa, H., Hata, S., & Hashimoto, S. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1005566 · Cited by 11
Serum immune checkpoint profiling identifies soluble CD40 as a biomarker for pancreatic cancer
Digomann, D., Heiduk, M., Reiche, C., Glück, J., Kahlert, C., Mirtschink, P., Klimová, A., Bösch, F., Tonn, T., Gaedcke, J., et al. (2023) · npj Precision Oncology · doi:10.1038/s41698-023-00459-9 · Cited by 9
Cellular collusion: cracking the code of immunosuppression and chemo resistance in PDAC
Musiu, C., Lupo, F., Agostini, A., Lionetto, G., Bevere, M., Paiella, S., Carbone, C., Corbo, V., Ugel, S., & Sanctis, F. D. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1341079 · Cited by 10
Zou, S., Zhang, L., Jiang, C., Li, F., Yang, Y., Deng, X., Zhang, J., Chen, H., Jiang, L., Cheng, X., et al. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.217134 · Cited by 10
Self-citationThe Road Ahead in Pancreatic Cancer: Emerging Trends and Therapeutic Prospects
Do, C. T. P., Prochnau, J. Y., Domínguez, A. M., Wang, P., & Rao, M. K. (2024) · Biomedicines · doi:10.3390/biomedicines12091979 · Cited by 10
Wang, H., Hung, W., Chen, L., & Pan, M. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19113584 · Cited by 9
Veatch, J. R., Singhi, N., Jesernig, B. L., Paulson, K. G., Zalevsky, J., Iacucci, E., Tykodi, S. S., & Riddell, S. R. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001591 · Cited by 10
The Combiome Hypothesis: Selecting Optimal Treatment for Cancer Patients
Hirsch, F. R., Walker, J., Higgs, B. W., Cooper, Z. A., Raja, R. G., & Wistuba, I. I. (2021) · Clinical Lung Cancer · doi:10.1016/j.cllc.2021.08.011 · Cited by 10
Charneau, J., Suzuki, T., Shimomura, M., Fujinami, N., Mishima, Y., Hiranuka, K., Watanabe, N., Yamada, T., Nakamura, N., & Nakatsura, T. (2022) · Cancer Science · doi:10.1111/cas.15291 · Cited by 10
Next-generation sequencing technologies accelerate advances in T-cell therapy for cancer
Yin, Q., Tang, J., & Zhu, X. (2018) · Briefings in Functional Genomics · doi:10.1093/bfgp/ely018 · Cited by 9
Immune defects in pancreatic cancer
Zheng, L. (2018) · Annals of Pancreatic Cancer · doi:10.21037/apc.2018.11.01 · Cited by 9
Mining the Gut Microbiota for Microbial-Based Therapeutic Strategies in Cancer Immunotherapy
Li, B., Gong, T., Hao, Y., Zhou, X., & Cheng, L. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.721249 · Cited by 9
Propionyl-CoA carboxylase subunit B regulates anti-tumor T cells in a pancreatic cancer mouse model
Han, H. V., Efem, R., Rosati, B., Lu, K., Maimouni, S., Jiang, Y., Montoya, V., Velden, A. W. M. V. D., Zong, W., & Lin, R. Z. (2024) · eLife · doi:10.7554/elife.96925.2 · Cited by 10
Chattopadhyay, S., Liao, Y., Wang, X., & Nel, A. E. (2023) · Bioengineering · doi:10.3390/bioengineering10101205 · Cited by 10
The role of the gut microbiome in regulating the response to immune checkpoint inhibitor therapy
Dean, N. J., d’Arienzo, P. D., Ibraheim, H., Lee, K. A., Olsson-Brown, A. C., Pinato, D. J., & Powell, N. (2024) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2024.101944 · Cited by 9
MCRS1 sensitizes T cell–dependent immunotherapy by augmenting MHC-I expression in solid tumors
Li, X., Han, Y., Jin, Z., Jiang, K., Xue, K., Wang, J., Qian, Y., Xiang, Q., Zhu, S., Yan, R., et al. (2024) · The Journal of Experimental Medicine · doi:10.1084/jem.20240959 · Cited by 8
Bacteria and tumor debris induced pancreatic cancer progression via the NF-κB signaling pathway
Chen, Q., Xu, Y., Wang, Y., Zheng, S., Yao, T., Qiu, J., Qin, H., & Liang, T. (2025) · Cancer Letters · doi:10.1016/j.canlet.2025.217964 · Cited by 12
Zhu, Q., Qiao, G., Huang, L., Xu, C., Guo, D., Wang, S., Zhao, J., Song, Y., Liu, B., Chen, Z., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.837560 · Cited by 8
Self-citationA metabolite of the gut microbiota: a facilitator of chemotherapy efficacy in cancer
Kwon, B. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01506-4 · Cited by 8
Hao, W., Chang, R., Liu, J., Wang, Y., Ren, M., Xin, K., Liu, B., Xie, J., & Yang, Y. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1356350 · Cited by 9
Larson, A. C., Knoche, S. M., Brumfield, G. L., Doty, K. R., Gephart, B. D., Moore-Saufley, P. R., & Solheim, J. C. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25063211 · Cited by 8
Tumor Antigens beyond the Human Exome
Emilius, L., Bremm, F., Binder, A. K., Schaft, N., & Dörrie, J. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25094673 · Cited by 9
Basar, E., Mead, H., Shum, B. O. V., Rauter, I., Ay, C., Skaletz‐Rorowski, A., & Brockmeyer, N. H. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16091207 · Cited by 11
Zi, R., Shen, K., Zheng, P., Su, X., Yang, Y., Chen, Y., Dai, H., Mao, C., Lu, Y., Wang, L., et al. (2025) · The Innovation · doi:10.1016/j.xinn.2024.100783 · Cited by 14
Li, G., Liu, T., Zheng, J., Kang, W., Xu, J., Gao, Z., & Ma, J. (2019) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-019-1217-z · Cited by 8
Chen, Y., Miao, S., & Zhao, W. (2021) · American Journal of Translational Research · Cited by 9
Lin, B., Pan, Y., Yu, D., Dai, S., Sun, H., Chen, S., Zhang, J., Xiang, Y., & Huang, C. (2021) · BioMed Research International · doi:10.1155/2021/5573628 · Cited by 8
Self-citationMartínez‐Cortés, F., Servín-Blanco, R., Domínguez‐Romero, A. N., Munguía, M. E., Valle, J. G., Odales, J., Gevorkian, G., & Manoutcharian, K. (2021) · Molecular Immunology · doi:10.1016/j.molimm.2021.08.013 · Cited by 9
Immunotherapeutic Strategies in Cancer and Atherosclerosis—Two Sides of the Same Coin
Nettersheim, F. S., Picard, F. S. R., Hoyer, F. F., & Winkels, H. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.812702 · Cited by 10
Jian, X., Xu, L., Zhao, J., Wang, Y., Zhou, W., & Xie, L. (2022) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2022.07.006 · Cited by 8
Self-citationImpact of microbiota-immunity axis in pancreatic cancer management
Bartolini, I., Nannini, G., Risaliti, M., Matarazzo, F., Moraldi, L., Ringressi, M. N., Taddei, A., & Amedei, A. (2022) · World Journal of Gastroenterology · doi:10.3748/wjg.v28.i32.4527 · Cited by 10
Carter, J. A., Matta, B., Battaglia, J., Somerville, C. C., Harris, B. D., LaPan, M., Atwal, G. S., & Barnes, B. J. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-007935 · Cited by 8
Ros, J., Baraibar, I., Vivancos, A. P., & Rodon, J. A. (2019) · Journal of Immunotherapy and Precision Oncology · doi:10.4103/jipo.jipo_19_19 · Cited by 8
Wang, D., Xu, W., Chen, W., Li, L., Yang, S., Zhang, J., & Tang, J. (2022) · Journal of Oncology · doi:10.1155/2022/9133636 · Cited by 11
Self-citationXiao, Y., Wu, L., & Guo, S. (2020) · Aquaculture · doi:10.1016/j.aquaculture.2020.736092 · Cited by 8
Imperial, R. J. L., Mosalem, O. M., Majeed, U., Tran, N. H., Borad, M. J., & Babiker, H. M. (2024) · Clinical and Experimental Gastroenterology · doi:10.2147/ceg.s390655 · Cited by 10
Pu, N., Chen, Q., Han, J., Xu, Z., Jiang, Z., He, T., An, Y., Xu, Y., Gan, W., Wang, H., et al. (2025) · International Journal of Surgery · doi:10.1097/js9.0000000000002733 · Cited by 9
Lahusen, A., Lutz, M. P., Fang, R., Kirchner, M., Albus, S., Kluck, K., Karthaus, M., Schwarzer, A., Siegler, G. M., Kleger, A., et al. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02406-7 · Cited by 8
Chiaro, J., Peltonen, K., Õunap, K., Bailey, A., Feola, S., Wojciechowski, S., Es-Haghi, M., Azkargorta, M., Elortza, F., Russo, S., et al. (2025) · npj Vaccines · doi:10.1038/s41541-025-01234-6 · Cited by 7
ImmunoStruct enables multimodal deep learning for immunogenicity prediction
Givechian, K. B., Rocha, J. F., Liu, C., Yang, E., Tyagi, S., Greene, K., Ying, R., Caron, É., Iwasaki, A., & Krishnaswamy, S. (2025) · Nature Machine Intelligence · doi:10.1038/s42256-025-01163-y · Cited by 18
Bever, K. M., Huff, A. L., Danilova, L., Wetzel, M., Tandurella, J. A., Durham, J. N., Wang, T., Lee, J. W., Coyne, E. M., Montagne, J. M., et al. (2026) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-25-0545 · Cited by 9
Kou, X., He, T., Zhang, M., Wu, X., Li, X., Luo, R., Wu, R., Gou, X., Shen, M., Wu, Q., et al. (2023) · Small Methods · doi:10.1002/smtd.202300019 · Cited by 10
The Value of Microbes in Cancer Neoantigen Immunotherapy
Tian, J., & Ma, J. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15082138 · Cited by 8
Top advances of the year: Pancreatic cancer
Warren, E. A. K., Lesinski, G. B., & Maithel, S. K. (2023) · Cancer · doi:10.1002/cncr.35031 · Cited by 8
Harnessing microbial antigens as cancer antigens: a promising avenue for cancer immunotherapy
Zhang, T., Zhang, X., Chen, J., Zhang, X., & Zhang, Y. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1411490 · Cited by 10
T lymphocyte‑related immune response and immunotherapy in gastric cancer (Review)
Zhang, Z., Zhang, W., Liu, X., Yan, Y., & Fu, W. (2024) · Oncology Letters · doi:10.3892/ol.2024.14670 · Cited by 7
Jia, Y., Li, J., Mei, W., Zhang, H., Wang, Z., Xie, X., Chongchong, G., Xu, X., & Li, F. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2025.114528 · Cited by 9
Veinalde, R., Pidelaserra-Martí, G., Moulin, C., Tan, C. L., Schäfer, T. E., Kang, N. H., Ball, C. R., Leichsenring, J., Stenzinger, A., Kaderali, L., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1096162 · Cited by 10
Ren, Z., Pan, B., Wang, F., Lyu, S., Zhai, J., Hu, X., Liu, Z., Li, L., Lang, R., He, Q., et al. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1112576 · Cited by 10
Dong, S., Zhong, A., Zhu, H., Wang, K., Cheng, C., & Meng, Z. (2023) · International Journal of Hyperthermia · doi:10.1080/02656736.2023.2278417 · Cited by 7
Advances in Surgery and (Neo) Adjuvant Therapy in the Management of Pancreatic Cancer
Liu, M., & Wei, A. C.-C. (2024) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2024.01.004 · Cited by 7
Vrecko, S., Guenat, D., Mercier‐Letondal, P., Faucheu, H., Dosset, M., Royer, B., Galaine, J., Boidot, R., Kim, S. C. H., Jary, M., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.26247 · Cited by 7
Difference in tumor mutation burden between squamous cell carcinoma in the oral cavity and larynx
Cui, J., Wang, D., Nie, D., Liu, W., Sun, M., Pei, F., & Han, F. (2021) · Oral Oncology · doi:10.1016/j.oraloncology.2020.105142 · Cited by 9
Immunosuppressive βig-h3 links tumour stroma and dysfunctional T cells in pancreatic cancer
Bauer, C. A. (2018) · Gut · doi:10.1136/gutjnl-2018-317735 · Cited by 7
Kaplon, H. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.835502 · Cited by 6
Talpin, A., Maia, A. R. R., Carpier, J.-M., Kulakowski, G., Aubergeon, L., Kervevan, J., Gaal, C., Strozzi, F., Billerey, C., Amable, L., et al. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-010192 · Cited by 9
Pakola, S. A., Ojala, N., Kudling, T. V., Clubb, J. H. A., Jirovec, E., van der Heijden, M., Arias, V., Haybout, L., Basnet, S., Grönberg-Vähä-Koskela, S. A. M., et al. (2025) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-025-04072-6 · Cited by 6
Type 2 diabetes alters quiescent pancreatic stellate cells to tumor-prone state
Hara, Y., Mizukami, H., Yamada, T., Shimoyama, S., Yamazaki, K., Sasaki, T., Wang, Z., Kushibiki, H., Ryuzaki, M., Ogasawara, S., et al. (2025) · JCI Insight · doi:10.1172/jci.insight.187424 · Cited by 6
Laethem, J. V., Geboes, K., Borbath, I., Macarulla, T. M., Lambert, A., Cassier, P. A., Prenen, H., Mitry, E., Blanc, J., Pilla, L., et al. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102407 · Cited by 14
Research progress on gut microbiota in colorectal cancer immunotherapy
Li, J., Yue, Y., Pan, J., & Liang, F. (2025) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2025.189476 · Cited by 7
Dendritic cell redundancy enables priming of anti-tumor CD4+ T cells in pancreatic cancer
Kureshi, C. T. S., Walsh, M. J., Kureshi, R., Cardot‐Ruffino, V., Agardy, D. A., Ali, L. R., Dougan, J. M., Li, Q., Shen, J., Zuo, C., et al. (2026) · Cancer Cell · doi:10.1016/j.ccell.2026.04.005 · Cited by 11
Deciphering the Tumor–Immune–Microbe Interactions in HPV-Negative Head and Neck Cancer
Hu, M., Coleman, S. S., Fadlullah, M. Z. H., Spakowicz, D. J., Chung, C. H., & Tan, A. C. (2023) · Genes · doi:10.3390/genes14081599 · Cited by 7
Zwart, E. S., van Ee, T., Doppenberg, D., Sarasqueta, A. F., Wilmink, J. W., Versteijne, E., Busch, O. R., Besselink, M. G., Meijer, L. L., van Kooyk, Y., et al. (2023) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-023-05219-7 · Cited by 7
Liu, Y., Jiang, X., Wu, Y., & Yu, H. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e27103 · Cited by 10
Lin, Q., Liang, L., Wang, Q., Wang, X., You, Y., Rong, Y., Zhou, Y., & Guo, X. (2024) · Biomedicines · doi:10.3390/biomedicines12040726 · Cited by 7
Zhou, S., Wang, Z., Zhao, D., Fu, Y., Zhang, S., Wang, Z., & Zou, X. (2024) · World Journal of Surgical Oncology · doi:10.1186/s12957-024-03409-2 · Cited by 6
Swidnicka-Siergiejko, A. K., Daniluk, J., Miniewska, K., Daniluk, U., Guzińska-Ustymowicz, K., Pryczynicz, A., Dąbrowska, M., Rusak, M., Ciborowski, M., & Dâbrowski, A. (2025) · Cells · doi:10.3390/cells14050361 · Cited by 10
Unraveling the glyco-immunity nexus in pancreatic cancer
Rajesh, C., Cummings, R. D., & Radhakrishnan, P. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02417-4 · Cited by 8
Metadata
- Authors
- Initiative, A. P. C. G., Balachandran, V. P., Łuksza, M., Zhao, J. N., Makarov, V., Moral, J. A., Remark, R., Herbst, B., Askan, G., Bhanot, U., Senbabaoglu, Y., Wells, D. K., Cary, C. I. O., Grbovic-Huezo, O., Attiyeh, M., Medina, B., Zhang, J., Loo, J., Saglimbeni, J., Abu-Akeel, M., Zappasodi, R., Riaz, N., Smoragiewicz, M., Kelley, Z. L., Basturk, O., Gönen, M., Levine, A. J., Allen, P. J., Fearon, D. T., Merad, M., Gnjatic, S., Iacobuzio-Donahue, C. A., Wolchok, J. D., DeMatteo, R. P., Chan, T. A., Greenbaum, B. D., Merghoub, T., & Leach, S. D.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- Parker Institute for Cancer Immunotherapy (US)
- Swim Across America (US)
- University of Cambridge (GB)
- Cold Spring Harbor Laboratory (US)
- Corresponding author
- Balachandran, Vinod P.
- ORCID
- Balachandran, Vinod P.
- Łuksza, Marta
- Zhao, Julia N.
- Makarov, Vladimir
- Herbst, Brian
- Bhanot, Umesh
- Wells, Daniel K.
- Grbovic-Huezo, Olivera
- Attiyeh, Marc
- Medina, Benjamin
- Zappasodi, Roberta
- Riaz, Nadeem
- Smoragiewicz, Martin
- Gönen, Mithat
- Levine, Arnold J.
- Fearon, Douglas T.
- Gnjatic, Sacha
- Wolchok, Jedd D.
- DeMatteo, Ronald P.
- Chan, Timothy A.
- Greenbaum, Benjamin D.
- Merghoub, Taha
- Leach, Steven D.
- Venue
- Nature
- Published
- 2017-11
- Volume
- 551
- Issue
- 7681
- Pages
- 512-516
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC6145146
- OpenAlex
- W2767699537
- Cited by
- 1,191
- References
- 28
- Citations by year
- 2026: 89 · 2025: 114 · 2024: 119 · 2023: 178 · 2022: 169 · 2021: 153 · 2020: 135 · 2019: 132 · 2018: 94 · 2017: 6
- FWCI
- 44.60
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (acceptedVersion)
- Cold Spring Harbor Laboratory Institutional Repository (Cold Spring Harbor Laboratory) (submittedVersion)
- Funders
- Pancreatic Cancer UK (RIF2015_A06_Jamieson)
- Wellcome Trust (103721/Z/14/Z)
- Cancer Research UK (23526, 17263, 15678)
- Academy of Medical Sciences (AMS-SGCL9-Jamieson)
- Agence Nationale de la Recherche (ANR-18-CE14-0005)
- National Institutes of Health
- National Cancer Institute (P01CA087497, P30-CA-08748, R01CA190400, P30CA008748, T32CA009501, K12CA184746)
- National Institute of Diabetes and Digestive and Kidney Diseases (R01DK097087)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- pancreatic ductal adenocarcinoma, long-term survival, neoantigens, CA125, CD8+ T cells, T cell immunity, immunogenicity, mutational burden, immune evasion
- MeSH terms
- Cancer Survivors, Exome Sequencing, Adenocarcinoma, Antigens, Neoplasm, Bacterial Proteins, Computer Simulation, Cross Reactions, Humans, Immunotherapy, Membrane Proteins, Pancreatic Neoplasms, Prognosis, T-Lymphocytes, Cytotoxic, Survival Analysis, CA-125 Antigen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.